| Brooks T. Grant, O.d., Pllc | |
|
6382 Buffalo Gap Rd Ste E, Abilene, TX 79606-6099 | |
| (325) 698-2010 | |
| (325) 692-2025 |
| Full Name | Brooks T. Grant, O.d., Pllc |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 6382 Buffalo Gap Rd Ste E, Abilene, Texas |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538434683 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 7554-TG (Texas) | Primary |
| Provider Name | Brooks Trent Grant |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1609189612 PECOS PAC ID: 3577731728 Enrollment ID: I20110714000428 |
News Archive
VG Life Sciences, a biotechnology company, announces today an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors.
Lombard Medical, Inc., a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today presented efficacy and safety data from the two-year follow up of the U.S. PYTHAGORAS pre-marketing approval (PMA) trial of Aorfix, the first and only endovascular stent graft with global approvals for the treatment of patients with aortic neck angulations up to 90 degrees.
The latest research from the team that discovered the novel anticancer agent FL118 highlights distinctive characteristics of this small-molecule compound and provides insights into its ability to overcome the persistent problem of treatment resistance. In findings reported in Molecular Cancer, Fengzhi Li, PhD, of Roswell Park Cancer Institute, and colleagues provide new evidence that FL118 may be more effective than two structurally similar injectable drugs and, additionally, may be effective as an oral agent.
A new study reveals in detail the changes that occur in peripheral blood natural killer (NK) and T cells in COVID-19.
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brooks T. Grant, O.d., Pllc 6382 Buffalo Gap Rd Ste E, Abilene, TX 79606-6099 Ph: (325) 698-2010 | Brooks T. Grant, O.d., Pllc 6382 Buffalo Gap Rd Ste E, Abilene, TX 79606-6099 Ph: (325) 698-2010 |
News Archive
VG Life Sciences, a biotechnology company, announces today an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors.
Lombard Medical, Inc., a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today presented efficacy and safety data from the two-year follow up of the U.S. PYTHAGORAS pre-marketing approval (PMA) trial of Aorfix, the first and only endovascular stent graft with global approvals for the treatment of patients with aortic neck angulations up to 90 degrees.
The latest research from the team that discovered the novel anticancer agent FL118 highlights distinctive characteristics of this small-molecule compound and provides insights into its ability to overcome the persistent problem of treatment resistance. In findings reported in Molecular Cancer, Fengzhi Li, PhD, of Roswell Park Cancer Institute, and colleagues provide new evidence that FL118 may be more effective than two structurally similar injectable drugs and, additionally, may be effective as an oral agent.
A new study reveals in detail the changes that occur in peripheral blood natural killer (NK) and T cells in COVID-19.
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.
› Verified 5 days ago
E. Russell Dressen, Jr. Od Optometrist Medicare: Not Enrolled in Medicare Practice Location: 942 Hickory St, Abilene, TX 79601 Phone: 325-677-6331 | |
Advanced Eyecare & Vintage Eyewear Optometrist Medicare: Not Enrolled in Medicare Practice Location: 4749 Buffalo Gap Rd, Abilene, TX 79606 Phone: 325-692-9596 Fax: 325-690-6191 | |
Texas Lone Star Eye Associates Inc Optometrist Medicare: Medicare Enrolled Practice Location: 4310 Buffalo Gap Rd Ste 1450, Abilene, TX 79606 Phone: 325-692-1627 Fax: 325-690-9905 | |
Big Country Eye Center Optometrist Medicare: Medicare Enrolled Practice Location: 4342 Treanor Dr, Abilene, TX 79602 Phone: 325-673-0900 | |
Abilene Advanced Eyecare Inc. Optometrist Medicare: Medicare Enrolled Practice Location: 4734 S 14th, Abilene, TX 79605 Phone: 325-692-9596 Fax: 325-690-6191 | |
Dr. Rama R Carson, OPTOMETRIST Optometrist Medicare: Accepting Medicare Assignments Practice Location: 4310 Buffalo Gap Rd Ste 1450, Abilene, TX 79606 Phone: 325-692-1627 Fax: 325-690-9905 | |
Med Southwest, Pllc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3225 S 27th St, Abilene, TX 79605 Phone: 325-691-0101 Fax: 325-691-8950 |